Predict your next investment

Corporation
HEALTHCARE | Medical Devices & Equipment / Patient Monitoring
chf-solutions.com

See what CB Insights has to offer

Founded Year

1999

Stage

IPO - II | IPO

Total Raised

$32.3M

About CHF Solutions

CHF Solutions is an early-stage medical device company focused on commercializing the Aquadex FlexFlow® System. The company's commercial product, the Aquadex system, is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.

CHF Solutions Headquarter Location

12988 Valley View Road

Eden Prairie, Minnesota, 55344,

United States

952-345-4200

Latest CHF Solutions News

Biomarkers can serve as tools to maintain kidney health for patients with CKD

Nov 4, 2021

Source: Coco S. Application of biomarkers to diagnose patients at risk of diabetic kidney disease: Where are we? Disclosures: Coco reports being employed by Icahn School of Medicine at Mount Sinai, which owns part of Renalytix; being a consultant for Renalytix, Takeda, CHF Solutions, Vifor, Bayer, Reprieve Cardiovascular, Axon and 3ive; having ownership interest in Renalytix and pulseData; receiving research funding from Renalytix, ProKidney, RRI and XORTX; having patents or inventions from Renalytix; and being a scientific advisor or member of Renalytix and Reprieve Cardiovascular. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio Biomarkers can identify patients at high risk for diabetic kidney disease, as well as help nephrologists make early clinical decisions to slow its progression, according to a speaker at ASN Kidney Week. Steven Coco “We need to do this because we cannot keep that status quo where people are referred at late stages, then you talk about dialysis or transplant,” Steven Coco, DO, MS, associate professor of medicine at Icahn School of Medicine at Mount Sinai, said during the virtual meeting. “We have the power to slow the progression in the early stages when there is not irreversible fibrosis and we can make a significant modification of the kidney disease trajectory.” Coco said to identify high-risk patients with biomarkers and optimize clinical outcomes, nephrologists cannot “go from zero to 60 in 3 seconds.” There is currently some reluctance to use biomarkers, he said. However, their use can help guide management of diabetic kidney disease. Additionally, risk stratification of patients with prognostic biomarkers, would help inform clinical decisions, he said. “Low-risk, less aggressive [diabetic kidney disease], maybe say ‘OK hold onto for now.’ But as they [patients] get into medium or higher risk, there is no excuse. Use the guideline recommended therapy and try to slow progression. You really have the motivation – not only on the physician side but also the patient side – to get on a multiple drug therapy for diabetic kidney disease.” Coco said a key tool to find and manage the high-risk patients involves integrating levels of the relevant biomarkers. He said KidneyIntel X was created as a diagnostic tool to assess patients’ risk level for progressive kidney function decline. It integrates the three strongest biomarkers – sTNFR-1, sTNFR-2 and KIM-1 with clinical variables to predict the risk of progression of diabetic kidney disease. “It is really about maintaining kidney health and not talking about end-stage kidney disease or kidney failure,” Coco said. Read more about

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing CHF Solutions

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

CHF Solutions is included in 1 Expert Collection, including Medical Devices.

M

Medical Devices

3,500 items

https://www.advamed.org/membership-join/membership-directory/ - excludes those without working websites.

CHF Solutions Patents

CHF Solutions has filed 35 patents.

The 3 most popular patent topics include:

  • Cardiac anatomy
  • Cardiology
  • Cardiovascular physiology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/18/2017

3/10/2020

Implants (medicine), Neurotechnology, Neurophysiology, Muscular system, Cardiology

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

10/18/2017

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

3/10/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Implants (medicine), Neurotechnology, Neurophysiology, Muscular system, Cardiology

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CHF Solutions Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

CHF Solutions Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.